Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type
Md Abdus Subhan, Farzana Parveen, Hassan Shah, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2204-2204
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Simultaneous blockade of the CD73/EGFR axis inhibits tumor growth
Keivan Ardeshiri, Hadi Hassannia, Ghasem Ghalamfarsa, et al.
IUBMB Life (2025) Vol. 77, Iss. 1
Closed Access | Times Cited: 1
A Review on Integrating Breast Cancer Clinical Data: A Unified Platform Perspective
Ram Mohan Ram Kumar, Suresh Joghee
Current Treatment Options in Oncology (2025)
Closed Access
Cellular Epigenetic Targets and Epidrugs in Breast Cancer Therapy: Mechanisms, Challenges, and Future Perspectives
Ibrahim S. Alalhareth, Saleh M. Alyami, Abdulrhman Alshareef, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 207-207
Open Access
Breast Cancer-the-State-of-the Art in the World and Islamic Development Banks Members Countries (IsDB-MCs)
Ahmed A. M. Elnour
(2025), pp. 169-213
Closed Access
New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy
Hanna Chowaniec, Antonina Ślubowska, Magdalena Mroczek, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 5
Disintegrin-like Protein Strategy to Inhibit Aggressive Triple-Negative Breast Cancer
Inès Limam, Mohamed Abdelkarim, Mohamed El Ayeb, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12219-12219
Open Access | Times Cited: 11
Triple-negative breast cancer: from none to multiple therapeutic targets in two decades
Filomena Marino Carvalho
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 11
Harnessing the synergistic potential of NK1R antagonists and selective COX-2 inhibitors for simultaneous targeting of TNBC cells and cancer stem cells
Madhu Tanya Singh, Praveen Thaggikuppe Krishnamurthy, Magham Sai Varshini
Journal of drug targeting (2024) Vol. 32, Iss. 3, pp. 258-269
Closed Access | Times Cited: 3
Precision medicine in breast cancer (Review)
Petros Papalexis, Vasiliki Georgakopoulou, Panagiotis Drossos, et al.
Molecular and Clinical Oncology (2024) Vol. 21, Iss. 5
Open Access | Times Cited: 3
Identification of a novel inflammation-related gene signature for predicting inflammatory breast cancer survival
Weiyu Bai, Qinggang Hao, Zhimeng Zhang, et al.
Genome Instability & Disease (2023) Vol. 4, Iss. 3, pp. 154-175
Closed Access | Times Cited: 9
Prognostic significance of HALP score and combination of peripheral blood multiple indicators in patients with early breast cancer
Zirui Zhao, Lingyun Xu
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 8
Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions
Shivangi Kumari, Sonam Raj, M. Arockia Babu, et al.
Archives of Pharmacal Research (2023) Vol. 47, Iss. 1, pp. 40-65
Closed Access | Times Cited: 8
A non-negative spike-and-slab lasso generalized linear stacking prediction modeling method for high-dimensional omics data
Junjie Shen, Shuo Wang, Yongfei Dong, et al.
BMC Bioinformatics (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Investigating the effects of artificial intelligence on the personalization of breast cancer management: a systematic study
Solmaz Sohrabei, Hamid Moghaddasi, Azamossadat Hosseini, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Flurbiprofen Clubbed Schiff's Base Derivatives as Potent Anticancer Agents: In Vitro and In Silico Approach towards Breast Cancer
Aftab Alam, Faizullah Khan, Najeeb Ur Rehman, et al.
Journal of Molecular Structure (2024) Vol. 1321, pp. 139743-139743
Closed Access | Times Cited: 2
Integrated and hyaluronic acid-coated mesoporous silica nanoparticles conjugated with cisplatin and chlorin e6 for combined chemo and photodynamic cancer therapy
Yi Li, V.H. Giang Phan, Zhouyi Pan, et al.
European Polymer Journal (2024) Vol. 220, pp. 113426-113426
Closed Access | Times Cited: 2
Seizing the moment: The time for harnessing electronic patient-reported outcome measures for enhanced and sustainable metastatic breast cancer care is now
Kelly M. de Ligt, Linetta B. Koppert, Belle H. de Rooij, et al.
The Breast (2024) Vol. 74, pp. 103676-103676
Open Access | Times Cited: 1
Integrated and Hyaluronic Acid-Coated Mesoporous Silica Nanoparticles Conjugated with Cisplatin and Chlorin E6 for Combined Chemo and Photodynamic Cancer Therapy
Yi Li, Xueting Xuan, Hong Yang, et al.
(2024)
Closed Access | Times Cited: 1
Gemcitabine Hydrochloride Drug-Delivery System Based on Folic Acid/Gold Nanoparticle Co-Modified Red Blood Cells for Breast Cancer Treatment
Jiyuan Xie, Ruonan Rong, Hongyu Zhong, et al.
ACS Applied Nano Materials (2024) Vol. 7, Iss. 9, pp. 10498-10510
Closed Access | Times Cited: 1
Medicinal Mushrooms in Metastatic Breast Cancer: What Is Their Therapeutic Potential as Adjuvant in Clinical Settings?
Fabrizio De Luca, Elisa Roda, Paolo Rossi, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 7, pp. 7577-7591
Open Access | Times Cited: 1
Therapeutic delivery of siRNA for the management of breast cancer and triple-negative breast cancer
Boya Manasa Sai, Yirivinti Hayagreeva Dinakar, Hitesh Kumar, et al.
Therapeutic Delivery (2024), pp. 1-21
Closed Access | Times Cited: 1
Advancements in pathology: Digital transformation, precision medicine, and beyond
S. Ahuja, Sufian Zaheer
Journal of Pathology Informatics (2024), pp. 100408-100408
Open Access | Times Cited: 1
Disintegrin-like protein strategy to inhibit aggressive triple negative breast cancer
Inès Limam, Mohamed Abdelkarim, Mohamed El Ayeb, et al.
(2023)
Open Access | Times Cited: 3
Adverse Crosstalk between Extracellular Matrix Remodeling and Ferroptosis in Basal Breast Cancer
Christophe Desterke, Emma Cosialls, Yao Xiang, et al.
Cells (2023) Vol. 12, Iss. 17, pp. 2176-2176
Open Access | Times Cited: 3
Adverse Crosstalk Between Extracellular Matrix Remodeling and Ferroptosis in Basal Breast Cancer
Christophe Desterke, Emma Cosialls, Yao Xiang, et al.
(2023)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top